| Description |
D13-9001 is a potent AcrB (AcrAB-TolC efflux pump subunit) and MexB (MexAB-OprM efflux pump subunit) inhibitor with the KD values of 1.15 μM and 3.57 μM in E. coli and P. aeruginosa, respectively[1]. D13-9001 exhibits antibiotic activities[2].
|
| Related Catalog |
|
| Target |
KD: 1.15 μM (AcrB), 3.57 μM (MexB)[1]
|
| In Vitro |
D13-9001 exhibits high solubility and a good safety profile[3].
|
| In Vivo |
D13-9001 (1.25-20 mg/kg; intravenous drip infusion; 2 hours) with aztreonam (AZT) gives improved survival rates in a lethal pneumonia rats at the end of day seven compared with AZT treated alone[3]. Animal Model: SD rats (Pulmonary infection by P. aeruginosa PAM1020)[3] Dosage: 1.25 mg/kg, 5 mg/kg, 20 mg/kg Administration: Intravenous drip infusion; 2 hours Result: The combination of 1.25, 5, and 20 mg/kg of D13-9001 with 1000 mg/kg of AZT gave improved survival rates at the end of day seven, whereas no obvious effect was observed on treatment with AZT alone.
|
| References |
[1]. Opperman TJ, et al. Recent advances toward a molecular mechanism of efflux pump inhibition. Front Microbiol. 2015 May 5; 6:421. [2]. Zuo Z, et al. Insights into the Inhibitory Mechanism of D13-9001 to the Multidrug Transporter AcrB through Molecular Dynamics Simulations. J Phys Chem B. 2016 Mar 10;120(9):2145-54. [3]. Yoshida K, et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg Med Chem. 2007 Nov 15;15(22):7087-97.
|
